Medical Technology

Seattle – October 30, 2026 -- Millennium Dental Technologies, Inc. said 49% of active U.S. members of the American Academy of Periodontology (AAP) are now trained in its LANAP protocol, a laser-based alternative to traditional osseous surgery for moderate to severe periodontitis. The company announced the figure at the AAP Annual Meeting in Seattle.

Adoption reaches roughly half of active U.S. periodontists in the AAP

The company, which developed LANAP and manufactures the PerioLase MVP-7 variable-pulsed Nd:YAG dental laser, said both periodontists and general dentists are adopting the protocol. LANAP is available only with the PerioLase MVP-7, which ties each new trained clinician to the company's hardware platform.

Founder, President and Chairman Robert H. Gregg II, DDS, said the milestone matters because "patients have greater access to care they can feel comfortable accepting."

PHOENIX – October 29, 2026 -- Dr. Jason Patterson of OrthoArizona is the first surgeon worldwide to perform total ankle replacement with Stryker's Prophecy Incompass patient-specific instrumentation, completing three procedures in July 2026.

Prophecy builds a 3D-printed surgical guide from the patient's CT scan

The system uses each patient's own CT scan to produce a custom 3D-printed guide before surgery begins. Paired with Stryker's Incompass total ankle system, it lets surgeons switch between stemmed and pegged implants mid-procedure if the exposed joint anatomy requires it.

Patterson has used CT-guided, patient-specific instrumentation for ankle replacement since 2015. He said the latest generation makes implant placement more consistent and surgery more efficient. In his words, the technology lets him plan around a specific patient's anatomy "instead of relying on a generic template."

Frankfurt am Main – October 29, 2026 -- Germany recorded 772 postmortem organ donors from January to September 2026, up 28 or 3.8% on the same period last year, the Deutsche Stiftung Organtransplantation (DSO) said at the opening of its 22nd Annual Congress.

Organs removed in Germany and allocated through Eurotransplant for transplantation at home or abroad totaled 2,373, compared with 2,258 a year earlier, a gain of 115 organs.

DSO says about 8,000 patients still wait for a donor organ

DSO Medical Director Dr. Axel Rahmel said the positive trend from last year continues but remains well short of what is needed for the roughly 8,000 people on German waiting lists. He cited the lack of a documented decision by potential donors as a key reason for low numbers. Most Germans view donation favorably, but few record that stance in writing, and the resulting uncertainty often leads relatives to refuse consent.

Boca Raton – October 19, 2026 -- Empyrean Medical Systems has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration for Vektra, its robotically assisted brachytherapy and intraoperative radiation therapy (IORT) system, completing a planned milestone in the company's move into clinical radiation oncology.

Vektra targets a segment treating about 15% of radiation oncology patients

Empyrean describes Vektra as the world's first robotically assisted, rapid beam-sculpting X-ray photon platform for brachytherapy and IORT. The system is designed to deliver conformal doses to malignant tumors while limiting dose to healthy tissue and organs at risk. Brachytherapy and IORT together treat approximately 15% of patients receiving radiation oncology care, according to the International Atomic Energy Agency (IAEA) figure cited by the company.

Boston – October 17, 2026 -- AdvaMed will host The MedTech Conference October 18–21 in Boston, with programming across more than seven stages and over 20 focus areas and a keynote panel of three medtech chief executives.

Three medtech CEOs headline the featured keynote discussion

The featured session, "Pulse of Medtech: Where the Industry Is Going Next," brings together Mick Farrell of Resmed, Mike Mahoney of Boston Scientific and Ashley McEvoy of Insulet. John Babitt of EY will moderate.

Attendee list preview shows registrants across the value chain

AdvaMed has published the first 2026 Attendee List Preview. It includes CEOs, senior executives and professionals in business development, strategy, regulatory affairs, policy, investment and innovation. Registrants span leading global companies, emerging innovators, investors, service providers and other medtech ecosystem organizations.

New York – October 14, 2026 -- Fesarius Therapeutics will present its DermiSphereTM hDRT dermal regeneration template at Plastic Surgery The Meeting (PSTM) 2026, October 15–18 at the George R. Brown Convention Center in Houston, Texas. The company will also appear at an event hosted by ASPS Ventures, the medtech venture fund.

Fesarius schedules a one-hour scientific symposium on October 17

The session, "From Benchtop to Bedside - Advancing Dermal Regeneration with Hydrogel Technology," runs 3:30–4:30 p.m. CDT in Innovation Theater B, Exhibit Hall DE. It will cover the science and clinical application of DermiSphereTM hDRT, including its dual-density microarchitecture, recently published clinical data and surgeon experience across complex wound and reconstructive applications.

Santa Cruz, Calif. – October 02, 2026 -- Emboline, Inc. completed the first commercial use of its Emboliner® Embolic Protection System in the United States on October 1, 2026, just weeks after receiving U.S. Food and Drug Administration 510(k) clearance.

Two TAVR procedures mark Emboline's commercial debut

The device was deployed during two transcatheter aortic valve implantation (TAVR) procedures performed by Tamim Nazif, MD, Co-Director of the Structural Heart and Valve Center at New York-Presbyterian/Columbia University Irving Medical Center. Dr. Nazif also serves as Co-Principal Investigator of the PROTECT H2H clinical trial, which evaluated the Emboliner's performance ahead of regulatory approval.

Tianjin, China – October 02, 2026 -- Tianjin University's "Shengong-Shengao" system has become China's first approved brain-computer interface (BCI) medical device for diagnosing cognitive impairment, cutting diagnosis time for conditions like hydrocephalus from days to just 30 minutes. The milestone marks a commercial breakthrough as TJU, China's first modern university, marks its 131st anniversary on October 2, 2026.

Shengong device line moves from lab to clinical wards nationwide

Developed by a team led by Professor Liu Xiuyun, the Shengong-Shengao system received regulatory approval and has already been joined by more than 20 additional devices in the Shengong series now deployed in clinical settings. The university states the devices have delivered measurable benefits to thousands of patients, signaling rapid translation of university research into deployable medical hardware.

Roggwil, Switzerland – September 29, 2026 -- Honest Lasers has launched the Honest Pro, a Swiss-manufactured diode laser system combining three wavelengths and integrated contact cooling for aesthetic and medical clinics worldwide.

Three wavelengths operate within a single clinical platform

The Honest Pro integrates 755 nm, 808 nm, and 1064 nm wavelengths in one system, each targeting melanin at different tissue depths to allow practitioners to treat varied hair and skin types without switching devices. The system runs at a maximum pulse rate of 10 Hz, which Honest Lasers designed for stable fluence delivery across repeated treatments during a full clinic workday.

Boston – September 27, 2026 -- Leo Cancer Care has confirmed a dedicated pediatric program combining education, distraction and gamification technology, following the world's first pediatric treatments delivered on its upright Marie® positioning and imaging platform.

Stanford Medicine delivers first upright pediatric proton treatments in June 2026

Stanford Medicine treated the initial pediatric patients using the Mevion S250-FIT Proton Therapy System, which integrates Leo Cancer Care's Marie platform and RaySearch Laboratories' RayStation planning software. The early cases demonstrated that upright proton therapy is feasible across a wide pediatric age range, with anesthesia still available when clinically required.